STA
ABBV icon

Summit Trail Advisors’s AbbVie ABBV Stock Holding History

Summit Trail Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14M Buy
64,582
+16,124
+33% +$3.58M 0.2% 61
2025
Q4 		$11.1M Sell
48,458
-435
-0.9% -$99.1K 0.19% 71
2025
Q3 		$11.3M Buy
48,893
+5,855
+14% +$1.19M 0.16% 78
2025
Q2 		$7.99M Buy
43,038
+7,018
+19% +$1.3M 0.14% 86
2025
Q1 		$7.55M Buy
36,020
+6,544
+22% +$1.27M 0.25% 42
2024
Q4 		$5.24M Buy
29,476
+5,053
+21% +$929K 0.19% 42
2024
Q3 		$4.82M Buy
24,423
+3,865
+19% +$721K 0.12% 81
2024
Q2 		$3.53M Buy
20,558
+2,924
+17% +$484K 0.09% 94
2024
Q1 		$3.21M Sell
17,634
-2,608
-13% -$449K 0.09% 90
2023
Q4 		$3.14M Buy
20,242
+920
+5% +$134K 0.1% 72
2023
Q3 		$2.88M Buy
19,322
+1,801
+10% +$264K 0.11% 78
2023
Q2 		$2.36M Buy
17,521
+10,856
+163% +$1.59M 0.09% 93
2023
Q1 		$1.06M Buy
6,665
+400
+6% +$61.2K 0.04% 122
2022
Q4 		$1.01M Buy
6,265
+402
+7% +$61.6K 0.05% 116
2022
Q3 		$787K Buy
5,863
+2,719
+86% +$390K 0.04% 125
2022
Q2 		$482K Sell
3,144
-17
-0.5% -$2.6K 0.03% 194
2022
Q1 		$512K Buy
3,161
+715
+29% +$104K 0.04% 168
2021
Q4 		$331K Buy
2,446
+43
+2% +$5.08K 0.02% 214
2021
Q3 		$259K Buy
+2,403
New +$275K 0.02% 220
2020
Q4 		– Sell
-3,584
Closed -$354K – 187
2020
Q3 		$354K Buy
+3,584
New +$337K 0.07% 132
2019
Q1 		– Sell
-3,497
Closed -$322K – 84
2018
Q4 		$322K Sell
3,497
-3,724
-52% -$327K 0.11% 76
2018
Q3 		$683K Buy
7,221
+3,497
+94% +$332K 0.15% 81
2018
Q2 		$345K Sell
3,724
-8,084
-68% -$790K 0.12% 97
2018
Q1 		$997K Sell
11,808
-1,081
-8% -$119K 0.17% 135
2017
Q4 		$1.33M Buy
+12,889
New +$1.21M 0.17% 121

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Summit Trail Advisors's ABBV Position: Q1 2026 in Review

Summit Trail Advisors increased its AbbVie (ABBV) stake by 33% in Q1 2026, buying an estimated $3.58M and bringing the position to 64,582 shares worth $14M. The position accounts for 0.2% of the portfolio, ranked #61.

Summit Trail Advisors first reported a position in ABBV in Q4 2017 and has held it in 25 quarters since. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Summit Trail Advisors held 64,582 shares of AbbVie worth $14M as of Q1 2026.
  • Summit Trail Advisors bought 16,124 AbbVie shares in Q1 2026, an estimated $3.58M.
  • AbbVie made up 0.2% of Summit Trail Advisors's portfolio in Q1 2026, its #61 holding.
  • Summit Trail Advisors first reported a position in AbbVie in Q4 2017 and has held it in 25 quarters since.
  • 4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Summit Trail Advisors's 13F filing for Q1 2026, filed 12 May 2026.